Physician profile
Donna Draper
NPI 1912212358
$19,190.90
in general payments reported to CMS, 2019-2025
33 companies · $4,648 in 2025
The $4,648 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,343 · 2022: $3,781 · 2023: $3,217 · 2024: $4,203 · 2025: $4,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,889.30 |
| Education | $177.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,969.32 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,894.07 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $1,730.58 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $1,711.84 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,350.27 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $1,240.11 | 2021-2025 | Trintellix |
| Corium, LLC | $764.67 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $748.99 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Axsome Therapeutics, INC. | $728.24 | 2022-2025 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $669.01 | 2022-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $646.78 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $598.19 | 2021-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $492.24 | 2021-2025 | Fanapt, Hetlioz |
| Avanir Pharmaceuticals, INC. | $346.73 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $292.35 | 2021-2023 | Jornay Pm |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $287.64 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $230.49 | 2024-2025 | Rejoyn, Abilify Maintena, Abilify Asimtufii |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.69 | 2024-2025 | |
| Bausch Health US, LLC | $177.11 | 2021-2023 | Aplenzin, Wellbutrin |
| Jazz Pharmaceuticals INC. | $137.77 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $135.67 | 2022-2025 | Quviviq, Quviviq |
| Tris Pharma INC | $126.00 | 2022-2025 | Dyanavel Xr |
| Janssen Scientific Affairs, LLC | $111.25 | 2025 | Invega Sustenna, Invega Trinza |
| Almatica Pharma LLC | $104.47 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Merck Sharp & Dohme LLC | $75.85 | 2021-2022 | |
| Eisai INC. | $72.00 | 2021 | |
| Vertical Pharmaceuticals, LLC | $71.99 | 2024-2025 | Relexxii |
| Tempus Ai, INC | $70.04 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $59.17 | 2024-2025 | Cobenfy |
| Adlon Therapeutics L.P. | $58.18 | 2021 | |
| Neos Therapeutics, LP | $54.77 | 2023 | Adzenys Xr-Odt |
| Arbor Pharmaceuticals, INC. | $30.50 | 2021 | |
| Sage Therapeutics, LLC | $22.92 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Draper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.